Acute effect of hemodialysis on serum levels of the proinflammatory cytokines.
ABSTRACT Chronic inflammation is a common feature of end-stage renal disease, which carries a heightened risk of atherosclerosis and other co-morbid conditions. Dialysis treatment per se can bring additional risk factors for inflammation, such as increased risk of local graft and fistula infections, impure dialysate or bio-incompatible membranes. Our study was designed to determine whether a hemodialysis session leads to an acute substantial alteration in the plasma levels of the proinflammatory cytokines interleukin (IL)-6, IL-1beta and tumor necrosis factor (TNF)-alpha, the T-lymphocyte activation factor soluble IL-2 receptor (sIL-2R), and an inflammation mediator and chemotactic granulocyte factor, IL-8, in end-stage renal disease patients receiving chronic intermittent HD. In this study, 21 (12 male/nine female) patients undergoing chronic hemodialysis were enrolled. The acute effect of a hemodialysis session on serum cytokine concentrations was assessed by comparison of pre-hemodialysis and post-hemodialysis determinations. Serum IL-1beta, sIL-2R, IL-6, IL-8 and TNF-alpha levels were determined with chemiluminescence enzyme immunometric assays. A significant difference was not observed for IL-1beta, IL-6, TNF-alpha, and sIL-2R concentrations in pre-hemodialysis and post-hemodialysis specimens (p>0.05). Serum median (25th-75th percentiles) IL-8 concentration was 69.4 (34.9-110.3) pg/ml before hemodialysis, and decreased to 31.5 (18.0-78.8) pg/ml following hemodialysis (p: 0.006). Clearance of IL-8 increased by 0.47+/-0.08 pg/ml for each unit increase in pre-dialysis IL-8 (p<0.001) and decreased by 5.63+/-2.59 pg/ml for each unit increase in pre-dialysis urea mmol/l (p<0.05). In conclusion, the results of our study demonstrate that a hemodialysis session markedly decreases IL-8 concentration, which is significantly affected by pre-dialysis concentrations, indicating that removal of IL-8 is a concentration gradient-dependent action, but does not change the serum levels of IL-1beta, sIL-2R, IL-6, and TNF-alpha, underlining importance of the structural characteristics of the molecules.
- [Show abstract] [Hide abstract]
ABSTRACT: Abstract Background: Vitamin E-coated dialyzer may have an effect on oxidative stress and inflammation status in hemodialysis (HD) patients. Therefore, we performed a systematic review to assess the anti-oxidation and anti-inflammatory effects of vitamin E-coated dialyzer in HD patients. Methods: The randomized controlled trials (RCTs) and quasi-RCTs of vitamin E-coated dialyzer versus conventional dialyzer for HD patients were searched from multiple databases. We screened relevant studies according to predefined inclusion criteria and performed meta-analyses using RevMan 5.1 software. Results: Meta-analysis showed vitamin E-coated dialyzer therapy could significantly decrease the serum thiobarbituric acid reacting substances (TBARS) (SMD, -0.95; 95% CI, -1.28 to -0.61; p < 0.00001), oxLDL (SMD, -0.61; 95% CI, -1.04 to -0.19; p = 0.005), interleukin-6 (IL-6) (SMD, -0.65; 95% CI, -0.97 to -0.32; p < 0.0001) and C-reactive protein (CRP) levels (SMD, -0.46; 95% CI, -0.87 to -0.05; p = 0.03) compared with that of the control group. However, vitamin E-coated dialyzer did not result in increasing the total antioxidant status (TAS) (SMD, 0.23; 95% CI, -0.16 to 0.61; p = 0.25) and the fractional clearance of urea index (Kt/v) levels (MD, -0.07; 95% CI, -0.14 to 0.00; p = 0.06), in addition, there was no significant difference in plasma superoxide dismutase (SOD) level compared with that of the conventional dialyzer & oral vitamin E group (SMD, 0.28; 95% CI, -0.20 to 0.75; p = 0.26). Conclusions: Vitamin E-coated dialyzer can reduce the oxidative stress and inflammation status reflected by the decreasing of serum TBARS, oxLDL, CRP, and IL-6 levels, and this new dialyzer does not affect the dialysis adequacy.Renal Failure 02/2014; · 0.94 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Hemodialysis induces oxidative stress causing intravascular inflammation, which may cause endothelial dysfunction. We evaluated how hemodialysis-induced changes in blood affect the function of endothelial cells in in vitro culture. Serum samples were collected from 42 uremic patients treated with hemodialysis, one before the start of dialysis and the other one at the end of session. All patients were dialysed with polysulfone dialyzer. Concentrations of the inflammatory molecules carbonyl protein and metabolites of NO synthesis were measured in blood. Additionally, the effect of the serum obtained before and after dialysis on the function of endothelial cells in in vitro culture was studied. Hemodialysis caused increase of monocyte chemoattractant protein (MCP)-1 (+17%), hepatocyte growth factor (+91%), and pentraxin-3 (+30%) concentration in serum. Concentration of carbonyl protein was decreased by 30%. Decrease of blood level of asymmetric dimethylarginine (-25%) and nitrate/nitrites (-62%) was observed. Serum obtained after hemodialysis stimulated proliferation of endothelial cells (+10%) and synthesis of MCP-1(+11%) in these cells. Hemodialysis-induced intravascular inflammation changes the function of endothelial cells, which may lead to acceleration of atherosclerosis.Hemodialysis International 02/2014; · 1.44 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Hemodialysis (HD) and hemodiafiltration clear only with a low efficiency the plasma from interleukin-6 and p-cresol, two protein-bound uremic toxins associated with high cardiovascular risk in end stage renal disease. HFR Supra is a double-chamber hemodiafiltration system in which the ultrafiltrate returns to the patient after its regeneration through a resin cartridge that binds hydrophobic and protein-bound solutes. In the present study, we evaluated whether the HFR cartridge can also bind total p-cresol and IL-6 and remove them from the ultrafiltrate. We compared the levels of IL-6 and p-cresol in ultrafiltrate samples collected at the inlet (UFin) and at the outlet (UFout) of the cartridge at the start or at the end of a 240 min HFR session in 12 inflamed chronic HD patients. The pro-inflammatory activity of the ultrafiltrate samples was also determined by evaluating the changes that they induced in IL-6 mRNA expression and protein release in peripheral blood mononuclear cells from 12 healthy volunteers. IL-6 and p-cresol circulating levels were also assessed in peripheral plasma blood samples collected before and after HFR and, for comparison, a control HD. p-Cresol and IL-6 were lower in UFout than in UFin both at the start and at the end of the HFR session, suggesting that they were retained by the cartridge. IL-6 mRNA expression and release were lower in PBMC incubated with UFout collected at the end than with UFin collected at the start of HFR, suggesting that passage through the cartridge reduced UF pro-inflammatory activity. Plasma total p-cresol decreased by about 53% after HFR, and 37% after HD. IL-6 circulating values were unmodified by either these dialysis procedures. This study shows that the HFR-Supra cartridge retains total p-cresol and IL-6 in the ultrafiltrate and lowers plasma total p cresol but not IL-6 levels. ClinicalTrials.gov NCT01865773.PLoS ONE 04/2014; 9(4):e95811. · 3.53 Impact Factor
CHRONIC inflammation is a common feature of end-
stage renal disease, which carries a heightened risk of
atherosclerosis and other co-morbid conditions. Dia-
lysis treatment per se can bring additional risk
factors for inflammation, such as increased risk of
local graft and fistula infections, impure dialysate or
bio-incompatible membranes. Our study was de-
signed to determine whether a hemodialysis session
leads to an acute substantial alteration in the plasma
levels of the proinflammatory cytokines interleukin
(IL)-6, IL-1b and tumor necrosis factor (TNF)-a, the T-
lymphocyte activation factor soluble IL-2 receptor
(sIL-2R), and an inflammation mediator and chemo-
tactic granulocyte factor, IL-8, in end-stage renal
disease patients receiving chronic intermittent HD.
In this study, 21 (12 male/nine female) patients
undergoing chronic hemodialysis were enrolled.
The acute effect of a hemodialysis session on serum
cytokine concentrations was assessed by comparison
of pre-hemodialysis and post-hemodialysis determi-
nations. Serum IL-1b, sIL-2R, IL-6, IL-8 and TNF-a
levels were determined with chemiluminescence
enzyme immunometric assays.
A significant difference was not observed for IL-1b, IL-
6, TNF-a, and sIL-2R concentrations in pre-hemodia-
lysis and post-hemodialysis specimens (p ?/0.05).
Serum median (25th?/75th percentiles) IL-8 concen-
lysis, and decreased to 31.5 (18.0?/78.8) pg/ml
following hemodialysis (p: 0.006). Clearance of IL-8
increased by 0.479 /0.08 pg/ml for each unit increase
in pre-dialysis IL-8 (p B/0.001) and decreased by
5.639 /2.59 pg/ml for each unit increase in pre-
dialysis urea mmol/l (p B/0.05).
In conclusion, the results of our study demonstrate
that a hemodialysis session markedly decreases IL-8
concentration, which is significantly affected by pre-
dialysis concentrations, indicating that removal of IL-
8 is a concentration gradient-dependent action, but
does not change the serum levels of IL-1b, sIL?/2R, IL-
6, and TNF-a, underlining importance of the structur-
al characteristics of the molecules.
tration was 69.4 (34.9?/110.3) pg/ml before hemodia-
Key words: Hemodialysis, Proinflammatory cytokines,
Soluble interleukin-2 receptor, Interleukin-8, Clearance
Mediators of Inflammation, 12, 15?/19 (2003)
Acute effect of hemodialysis on
serum levels of the
Mehmet Tarakc ¸ıog ˘lu1,CA, Ays ¸e Binnur Erbag ˘ci1,
Celalettin Usalan2, Rukiye Deveci1and
Ramazan Kocabas ¸1
1Department of Biochemistry and Clinical
Biochemistry and2Department of Nephrology,
Gaziantep University, Medicine Faculty, 27310
S ¸ehitkamil Gaziantep, Turkey
Tel:? /90 342 3606060/7135
Fax:? /90 342 3601617
Recent evidence points to chronic inflammation as a
major contributor to morbidity and mortality in end-
stage renal disease (ESRD).1It has been proposed
that a chronic inflammatory state could account for
the high risk of ischemic heart disease in patients
with ESRD.2Malnutrition and chronic systemic in-
flammatory response syndrome not only co-exist in
uremia, but may also have a bi-directional cause and
effect relationship.3Also, anemia appears to be an
important element linking elevated proinflammatory
cytokine levels with poor patient outcomes.1
Although the uremic state itself may impair lym-
phocyte, granulocyte and monocyte/macrophage
function, defects in immunity can occur as a direct
consequence of therapy.4About 35?/65% of ESRD
patients receiving hemodialysis (HD) show signs of
inflammation, whereas the prevalence in pre-dialysis
patients may be somewhat lower.1Dialysis has been
associated with acute changes in the complement
activation, granulocyte markers, macrophage func-
tion, T-cell activation and the release of various
proinflammatory cytokines.4?6Actually, recent data
suggest that levels of the proinflammatory cytokines
in HD patients are eight-fold to 10-fold higher than in
healthy controls. Several studies have linked high
ISSN 0962-9351 print/ISSN 1466-1861 online/03/010015-05 – 2003 Taylor & Francis Ltd
levels of proinflammatory cytokines with poor out-
comes in renal patients. In contrast, high levels of
cytokines associated with better T cell function, such
as interleukin (IL)-2 and IL-12, were associated with a
survival advantage for these patients.1,7
Activation of the proinflammatory system in HD
patients may be due to three mechanisms. Suscept-
ibility to local graft and fistula infections, inflamma-
tory response induced by bioincompatible dialysis
membranes and exposure to contaminated dialysate
containing cytokine-inducing substances such as
endotoxins.1,3,8?10On the other hand, clearance or
membrane adsorption of cytokines during hemodia-
lysis may alter circulating cytokine levels.11,12
Our study was designed to determine whether a
HD session leads to an acute substantial alteration in
the plasma levels of cytokines in ESRD patients
receiving chronic intermittent HD. The proinflamma-
tory cytokines IL-6, IL-1b and tumor necrosis factor
(TNF)-a, the T-lymphocyte activation factor soluble
IL-2 receptor (sIL-2R), and an inflammation mediator
and chemotactic granulocyte factor, IL-8,13?16were
determined in sera specimens before and after HD.
Materials and methods
This study was conducted in 2001. Informed consent
was obtained from all subjects according to the
Helsinki declaration as revised in 1996. Twenty-one
patients (12 male/nine female) with chronic renal
impairment undergoing hemodialysis were recruited.
Mean age (9 /SD) was 47.39 /14.2 years. Body mass
index of the subjects was 20.09 /2.4 kg/m2. Patients
received an average of 12 h hemodialysis three times
a week on a non-reprocessed synthetic dialyzer using
polysulfone membranes: Fresenius F-6, 40 mm thick
of 1.3 m2surface area (F6 polysulfone UF 5.5;
Fresenius St, Wendel GmbH, Frankfurt, Germany).
Mean dialysis time was 3.79 /4.8 years. Patients
received no other medication except phosphate
binders, ferrous sulfate, essential amino acids and
angiotensin-converting enzyme inhibitors. The etiol-
ogy of the ESRDs was diabetes mellitus (n?/6),
hypertensive malign nephrosclerosis (n?/4), uro-
lithiasis (n?/4), polycystic kidney disease (n?/2),
chronic glomerulonephritis (n?/5).
Protocol and experimental study
Pre-HD and post-HD venous blood samples were
collected using standard venipuncture technique 20
min before and after HD, respectively, into plain
tubes. Sera were separated immediately after centri-
fugation at ? /48C, 2000 g for 10 min and stored at
? /208C for 1 month. Serum IL-1b, sIL-2R, IL-6, IL-8
Mediators of Inflammation? Vol 12? 2003
and TNF-a levels were determined with chemilumi-
nescence enzyme immunometric assays on an Im-
mulite Immunoassay Analyzer (Immulite DPC, Los
Angeles, CA, USA). Analytical sensitivities of IL-1b,
sIL?/2R, IL-6, IL-8, and TNF-a assays were 1.5 pg/ml,
10 U/ml, 1.0 pg/ml, 2.0 pg/ml and 1.7 pg/ml, and the
lower reportable ranges were 5.0 pg/ml, 50 U/ml, 5.0
pg/ml, 5.0 pg/ml and 4.0 pg/ml, respectively. Im-
mulite cytokine controls were included in each
analytical run. Intra-assay and inter-assay precision
performances of the assays were determined on 10
replicates in a single run and in 20 different runs,
respectively and yielded coefficients of variation
within the 4.2?/8.9% range.
Total protein, albumin and urea concentrations
were determined on a Roche/Hitachi modular analy-
tics system (Roche Diagnostics, Indianapolis, IN,
USA) with Roche reagents according to the manu-
Demographic data were expressed in terms of
mean9 /SD. The selected laboratory parameters are
presented as median (25th?/75th percentiles). IL-1b
was expressed as proportion of detectable (]/5.0 pg/
ml) cases. Paired differences were evaluated with the
paired samples t-test and the Wilcoxon signed-rank
test when necessary. Significant predictors of the
paired difference (pre-HD minus post-HD values) of
IL-8 levels were evaluated with univariate linear
regression analysis. Statistical significance of the
variables was established at the level pB/0.05. The
SPSS 9.0 (SPSS Inc., Chicago, IL, USA) program was
used for statistical analyses and illustrations.
Serum levels of the cytokines in samples taken before
and after HD were compared. IL-1b values in most
cases were below the detection limit. Three cases
with detectable IL-1b in pre-dialysis and four cases in
post-dialysis revealed p?/0.407 by Wilcoxon signed-
rank test. Significant differences were not observed
for IL-6, and sIL-2R concentrations in pre-HD and
post-HD specimens (p?/0.05). Serum median (25th?/
75th percentiles) IL-8 concentration was 69.4 (34.9?/
110.3) pg/ml before HD, and decreased to 31.5
(18.0?/78.8) pg/ml following HD (p?/0.006). A sig-
nificant increase for TNF-a (p?/0. 011) was noticed
during hemodialysis (Table 1).
Serum total protein and albumin concentrations
were significantly elevated after HD, a well-known
criteria for hemoconcentration.17By determining the
values of relatively big molecules, sIL-2R and TNF-a
per gram of total protein, we aimed to exclude
M. Tarakc ¸iog ˘lu et al.
possible effects of the hemoconcentration effect
(Table 1). After correction for hemoconcentration,
the increase in TNF-a concentration disappeared,
possibly indicating a hemoconcentration rather than
an absolute change in total serum. The paired
difference for sIL-2R remained insignificant after
correction for hemoconcentration. Pre-HD and post-
HD IL-8 concentrations of the patients are illustrated
in Fig. 1.
Results of univariate regression analysis paired
difference (PD) (pre-HD minus post-HD values) of
IL-8 levels as the dependent variable are presented in
Table 2. The model included pre-dialysis IL-8 values
representative of the concentration gradient (as the
dialysis solution does not contain any IL-8 at the
beginning of the session), pre-dialysis and PD urea
representative of accumulation and clearance of
freely diffusible molecules, and pre-dialysis and PD
of total protein concentrations representative of
hemoconcentration. Only pre-dialysis IL-8 and pre-
dialysis urea concentrations were significant predic-
tors of the PD IL-8. The relation with the PD of urea
did not reach the significance level (p?/0.091). The
PD, or in other words removal of IL-8, increased by
0.479 /0.08 pg/ml for each unit increase in pre-
dialysis IL-8 (pB/0.001) and decreased by 5.639 /
2.59 pg/ml for each 1.0 mmol/l increase in pre-
dialysis urea (pB/0.05). This model explains 58.7% of
the variation in PD IL-8 (pB/0.005).
The results of our study demonstrate that the serum
concentrations of IL-8 are decreased during HD but
IL-1b, sIL?/2R, IL-6, and TNF-a remained unchanged
over the course of measurement. Several studies
reported unchanged serum IL-6,9,11,18IL-1,9,19and
TNF-a18during HD concurrent with increased clear-
ance or membrane adsorption of these cytokines.7,11
The reasons for this phenomenon probably depend
on cytokine kinetics. The half-lives of IL-6 (3?/7 min),
and TNF-a (5?/10 min) are known to be rather short.
Since plasma cytokines are rapidly bound to cell
surface receptors, this implies that stable plasma
concentrations are achieved by a continuously high
production rate. As a consequence, the entire amount
of cytokines potentially eliminated via hemodialysis
is probably considerably lower when compared with
the endogenous production.18It is not unlikely that
the serum concentrations of cytokines serve as target
of feedback mechanisms, since their endocrine action
has been shown, apart from paracrine actions.20,21It
must also be taken into account that adsorption of
cytokines occurs mainly in the first minutes of HD
and may not reflect a substantial amount of cytokine
removal,18and HD membranes may increase cyto-
cells.9,10,12Magnitude and impact of biological varia-
tion of cytokines merit consideration for interpreta-
tion of the results of this study. Gonzales et al.
assessed within-subject coefficients of variation (CVi)
for cytokines by measurements at monthly intervals
over a period of six consecutive months in healthy
Mediators of Inflammation? Vol 12? 2003
Table 1. Circulating cytokine levels in pre-hemodialysis and post-hemodialysis specimens
Before hemodialysis After hemodialysis
Total protein (g/l)
TNF-a (pg/ml)/total protein (g/l)
sIL-2R (U/ml)/total protein (g/l)
Data presented as presented as median (25th?/75th percentiles).
*Significance after correction for hemoconcentration.
FIG. 1. Pre-hemodialysis and post-hemodialysis IL-8 concen-
trations of the patients arranged according to the pre-
hemodialysis IL-8 values in ascending order on a semi-
Cytokines and hemodialysis
individuals. The within-subject variation is the aver-
age variation of results around the homeostatic mean
of the individual. The CVi for IL-1b, IL-8, and TNF-a
were 30%, 24%, and 43%, respectively.22CVi for IL-6
was 30.5% in a short-term variability study.23These
data apparently indicate that the impact of biological
variation of the cytokines is large on numerical
results. So, it is possible to assume that any effect of
hemodialysis on IL-1b, sIL?/2R, IL-6, and TNF-a may
be masked by a biological variation of higher
magnitude. However, the expected intra-individual
variation of IL-8 (Cvi?/24%) is much smaller than the
CVi in our study (54.1%; data not shown). Therefore,
biological variation does not explain the observed
difference between pre-dialysis and post-dialysis IL-8
Diverse elimination kinetics of the studied cyto-
kines may be related to the differences in molecular
structure. IL-6 (26.5 kDa), TNF-a (biologically active
heterotrimeric form, 53 kDa), IL-1b (17.5 kDa), sIL?/
2R (varies, 55?/75 kDa) are relatively large molecules.
IL-8 is a low molecular weight protein (10 kDa) with
which possibly enables its diffusion through the
dialysis membrane. In our study, the significant effect
of pre-dialysis IL-8 levels on elimination of IL-8
observed may represent a concentration gradient,
confirming this diffusion effect. Alternative or addi-
tional possible mechanisms of the observed decrease
may be altered IL-8 production or stability, mem-
brane adsorption of IL-8, or IL-8 producing cells
during hemodialysis. It is now known that IL-8
production by various normal and pathological hu-
man cells can be either constitutive or can be induced
by various stimuli, such as lipopolysaccharide, leu-
kotrienes, IL-1, TNF-a. Several stress factors such as
hypoxia, acidosis, and nitric oxide (NO) significantly
influence expression of IL-8 in tumorogenic human
cells.14,20Xie suggested that NO serves as an intra-
cellular second messenger to regulate IL-8 gene
expression, increasing IL-8 protein secretion and
promoter activity. The rate of IL-8 gene transcription
was correlated with the level of IL-8 expression,
suggesting that a constitutive level of IL-8 gene
transcription was a major contributing factor in
Mediators of Inflammation? Vol 12? 2003
differential IL-8 expression.14Therefore, decreased
NO may be a contributing factor to decreased serum
IL-8.24The negative correlation of pre-dialysis urea
levels with the PD of IL-8, however, is an unexpected
finding and may simply result from a competition
between freely diffusible molecules or somewhat
lower pre-dialysis IL-8 levels in patients with higher
pre-dialysis urea concentrations.
Heering et al. have demonstrated removal of IL-8
from the circulation by continuous hemofiltration but
a reduction of plasma IL-8 levels is contradictory.25,26
Differences in the flow rates, amount of fluids and
nature of membranes as well as the differences in the
pathophysiology of the diseases (as they investigated
critically ill patients) in our study and the aforemen-
tioned studies may have implications on the observed
This study has some methodological limitations
that might contribute to the fact that we did not find a
significant difference for IL-1b. The majority of the
pre-HD and post-HD specimens had lower serum
levels than the detection limit of the assay, which
raises the possibility that phase differences might be
present below the detection limit. Another potential
limitation was the small number of the study group. A
larger study population and a longitudinal study
design, including more sessions, are needed to
elucidate whether these alterations are consistent.
In conclusion, the results of our study demonstrate
that a HD session markedly decreases IL-8 concen-
tration, which is significantly affected by pre-dialysis
concentrations, indicating that removal of IL-8 is a
concentration gradient-dependent action. But a HD
session does not change serum levels of IL-1b, sIL?/
2R, IL-6, and TNF-a, underlining importance of the
structural characteristics of the molecules.
1. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal
disease. Nephrol Dial Transplant 2001; 16: 36?/40.
2. Bolton CH, Downs LG, Victory JGG, et al. Endothelial dysfunction in
chronic renal failure: roles of lipoprotein oxidation and pro-inflamma-
tory cytokines. Nephrol Dial Transplant 2001; 16: 1188?/1197.
3. Schiffl H, Lang SM, Stratakis D, Fischer R. Effects of ultrapure dialysis
fluid on nutritional status and inflammatory parameters. Nephrol Dial
Transplant 2001; 16: 1863?/1869.
Table 2. Univariate linear regression analysis, paired difference (PD) (pre-hemodialysis minus post-hemodialysis values) of IL-
8 levels as the dependent variable
CovariateB 95% confidence intervalSignificance
Lower bound Upper bound
Pre-dialysis IL-8 (pg/ml)
Pre-dialysis total protein (g/l)
PD total protein (g/l)
Pre-dialysis urea (mmol/l)
PD urea (mmol/l)
? /309.0 225.4
M. Tarakc ¸iog ˘lu et al.
4. Zamauskaite A, Perez-Cruz I, Yaqoob MM, Madrigal JA, Cohen SBA.
Effect of renal dialysis therapy modality on T cell cytokine production.
Nephrol Dial Transplant 1999; 14: 49?/55.
5. Sester U, Sester M, Hauk M, Kaul H, Ko ¨hler H, Girndt M. T-cell activation
follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol
Dial Transplant 2001; 15: 1217?/1223.
6. Capelli G, DiFelice A, Perrone S, et al. Which level of cytokine
production is critical in haemodialysis? Nephrol Dial Transplant 1998;
7. Kimmel PL, Phillips TM, Simmens SJ, et al. Immunologic function and
survival in hemodialysis patients. Kidney Int 1998; 54: 236?/244.
8. Yamasaki H, Nishi H, Nagake Y, Mino Y, Makino H. Changes in CD14
expression on monocytes and changes in serum soluble CD14 level
during hemodialysis. Clin Exp Nephrol 2000; 4: 58?/62.
9. Girndt M, Heisel O, Ko ¨hler H. Influence of dialysis with polyamide vs.
haemophan haemodialysers on monokines and complement activation
during a 4-month long-term study. Nephrol Dial Transplant 1999; 14:
10. Gu Y, Ding F, Qin H, Zhao H, Lin S. Synergetic effect of dialyzer
membrane and lipopolysaccharide on peripheral blood mononuclear
cell cytokine production in uremic patients. Chin Med J 2000; 113: 315?/
11. Fujimori A, Naito H, Miyazaki T. Adsorption of complement, cytokines,
and proteins by different dialysis membrane materials: evaluation by a
confocal laser scanning flourescence microscopy. Artif Organs 1998; 22:
12. Lonnemann G, Koch KM, Shaldon S, Dinarello CA. Studies on the ability
of hemodialysis membranes to induce, bind and clear human inter-
leukin-1. J Lab Clin Med 1998; 112: 76?/86.
13. Fischer K, Hamza A, Eisman R, Amoury M, Heynemann H, Fornora P.
Differential diagnostic use of interleukin patterns in patients being
monitored after transplantation. Clin Chim Acta 2001; 310: 71?/80.
14. Xie K. Interleukin-8 and human cancer biology. Cytokine Growth Factor
Rev 2001; 12: 375?/391.
15. Hoffmann JN, Hartl WH, Faist E, Jochum M, Inthorn D. Tumor necrosis
factor measurement and use of different anticoagulants: possible
interference in plasma samples and supernatants from endotoxin-
stimulated monocytes. Inflamm Res 1997; 46: 342?/347.
16. Aukrust P, Berge RK, Ueland T, et al. Interaction between chemokines
and oxidative stress: possible role in acute coronary syndromes. J Am
Coll Cardiol 2001; 37: 485?/491.
17. Tarakc ¸iog ˘lu M, Erbag ˘cı AB,
.C ¸ekmen M, et al. Acute effect of
hemodialysis on serum markers of myocardial damage. Int J Clin Pract
2002; 56: 328?/332.
18. Sander A, Armbruster W, Sander B, Daul AE, Lange R, Peters J.
Hemofiltration increases IL-6 clearance in early systemic inflammatory
response syndrome but does not alter IL-6 and TNFa plasma concentra-
tions. Intensive Care Med 1997; 23: 878?/884.
19. Herbelin A, Nguyen AT, Zingraff J, Urena P, Descamps-Latscha B.
Influence of uremia and hemodialysis on circulating interleukin-1 and
tumor necrosis factor alpha. Kidney Int 1990; 37: 116?/125.
20. Massey HD, McPherson RA. Cytokines and adhesion molecules. In:
Henry JB, ed. Clinical Diagnosis and Management by Laboratory
Methods, Philadelphia: W.B. Saunders Co, 2001: 541?/616.
21. Santos-Rosa M, Bienvenu J, Whitcher J. Cytokines. In: Burtis CA,
Ashwood E, eds. Tietz Textbook of Clinical Chemistry, Philadelphia:
W.B. Saunders Co, 1999: 914?/926.
22. Gonzalez C, Cava F, Ayllo ´n A, et al. Biological variation of interleukin-
1b, interleukin-8, and tumor necrosis factor-a in serum of healthy
individuals. Clin Chem Lab Med 2001; 39: 836?/841.
23. Dugue ¯ B, Leppa ¨nen E. Short-term variability in the concentration of
serum interleukin-6 and its soluble receptor in subjectively healthy
persons. Clin Chem Lab Med 1998; 36: 323?/325.
24. Hon WM, Lee JC, Lee KH. Effect of hemodialysis on plasma nitric oxide
levels. Artif Organs 2000; 24: 387?/390.
25. Heering P, Morgera S, Schmitz EJ, et al. Cytokine removal and
cardiovascular hemodynamics in septic patients with continuous
venovenous hemofiltration. Intensive Care Med 1997; 23: 288?/296.
26. Millar AB, Armstrong L, van der Linden J, et al. Cytokine production and
hemofiltration in children undergoing cardiopulmonary bypass. Ann
Thorac Surg 1993; 56: 1499?/1502.
Received 2 October 2002
Accepted 2 December 2002
Cytokines and hemodialysis
Mediators of Inflammation? Vol 12? 200319